Rapid molecular tests revolutionize the TB diagnostic

2023-03-20

Tuberculosis background

Tuberculosis is a chronic infectious disease, which is caused by the mycobacterium tuberculosis complex and spread through respiratory droplets and dust. Pulmonary tuberculosis infection is the most common, and non pulmonary tuberculosis infection is called extrapulmonary tuberculosis. "The human body may not necessarily develop symptoms after being infected with tuberculosis. When resistance decreases or cellular mediated allergic reactions increase, clinical symptoms may occur. Patients typically experience anorexia, fatigue, chest pain, cough, coughing up blood, night sweats, and pale complexion."

Tuberculosis burden

The global situation of tuberculosis prevention and control is grim. According to the 2022 Global tuberculosis Report released by WHO, the number of new infections in the world in 2021 is estimated to be about 10.6 million, including 6 million adult males, 3.4 million adult females and 1.2 million children. Among them, 6.7% were HIV infected. Therefore, accurate diagnosis of tuberculosis patients and newly infected people, and moving forward the threshold of tuberculosis prevention, screening, diagnosis and treatment are crucial to ending the global tuberculosis epidemic.

Tuberculosis diagnosis

At present, the diagnostic techniques for tuberculosis mainly include sputum smear staining, bacterial culture method, immunological detection and PCR amplification of Mycobacterium tuberculosis. In clinical practice, positive etiology of tuberculosis patients is still the gold standard for laboratory diagnosis. However, due to the long period of sputum culture and low sensitivity of sputum smear, molecular PCR technology has been applied in tuberculosis laboratory diagnosis, reducing the diagnosis of tuberculosis and drug-resistant tuberculosis from weeks to hours.

In order to quickly find the source of infection in the early stage of tuberculosis, diagnose tuberculosis, clarify the drug resistance of tuberculosis, and help the clinical better implement treatment, uni-meidca launched a new product: Real time PCR Kit for Mycobacterium Tuberculosis RpoB Gene and Mutation. Using fluorescent quantitative PCR method, it can realize the simultaneous detection of Mycobacterium tuberculosis and rifampicin resistance in a sputum sample, Effectively improve the positive rate of tuberculosis etiology, report the results of rifampicin resistance, and predict multidrug resistant tuberculosis.

Total Solution for Molecular Diagnosis of Tuberculosis